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were interpreted as normal or abnormal for neuritic plaque 
density by each of five non-Japanese and five Japanese 
readers who were blinded to clinical data. The primary effi-
cacy analysis (based on HV and pAD data) was the agree-
ment of the non-Japanese readers’ image interpretations 
with the clinical diagnosis, resulting in estimates of posi-
tive percent agreement (PPA; based on AD subjects; simi-
lar to sensitivity) and negative percent agreement (NPA; 
based on HVs; similar to specificity). Secondary analyses 
included PPA and NPA for the Japanese readers; inter-
reader agreement (IRA); intra-reader reproducibility (IRR); 
quantitative image interpretations (standardized uptake 
value ratios [SUVRs]) by diagnostic subgroup; test–retest 
variability in five pAD subjects; and safety.
Abstract 
Objective This Phase 2 study assessed the performance 
of positron emission tomography (PET) brain images made 
with Flutemetamol F 18 Injection in detecting β-amyloid 
neuritic plaques in Japanese subjects.
Methods Seventy subjects (25 with probable Alzhei-
mer’s disease (pAD), 20 with amnestic mild cognitive 
impairment (aMCI), and 25 cognitively normal healthy 
volunteers[HVs]) underwent PET brain imaging after intra-
venous Flutemetamol F 18 Injection (185  MBq). Images 
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Results PPA was 92% for all non-Japanese readers and 
ranged from 88 to 92% for the Japanese readers. NPA 
ranged from 96 to 100% for both the non-Japanese readers 
and the Japanese readers. The majority image interpreta-
tions (the interpretations made independently by ≥3 of 5 
readers) resulted in PPA values of 92 and 92% and NPA 
values of 100 and 96% for the non-Japanese and Japanese 
readers, respectively. IRA and IRR were strong. Composite 
SUVR values (mean of multiple regional values) allowed 
clear differentiation between pAD subjects and HVs. Test–
retest variability ranged from 1.14 to 2.27%, and test–retest 
agreement of the blinded visual interpretations was 100% 
for all readers. Flutemetamol F 18 Injection was generally 
well tolerated.
Conclusions The detection of brain neuritic plaques in 
Japanese subjects using  [18F]Flutemetamol PET images 
gave results highly consistent with clinical diagnosis, with 
non-Japanese and Japanese readers giving similar results. 
Inter-reader agreement and intra-reader reproducibility 
were high for both sets of readers. Visual delineation of 
abnormal and normal scans was corroborated by quantita-
tive assessment, with low test–retest variability.
Trial registration Clinicaltrials.gov registration number 
NCT02813070.
Keywords [18F]Flutemetamol · Alzheimer’s disease · 
Radiotracer · β-Amyloid
Introduction
The rapid growth of the aged population in Japan [1] 
poses medical and economic challenges because of age-
associated diseases such as dementia, of which the prev-
alence increased significantly from 1985 to 2005 [2]. 
Alzheimer’s disease (AD) is the predominant type of 
dementia in the Japanese population, [1, 2] with an inci-
dence rate comparable to that of Western populations [3]. 
The presence of amyloid plaques in the brain is one of 
the microscopic hallmarks of AD. While the presence of 
amyloid plaques is necessary but not sufficient for a path-
ological diagnosis of AD, an absence of plaques excludes 
AD. The amyloid plaques of AD result from aggregation 
of amyloid-beta (Aβ) peptides formed by secretase-cata-
lyzed cleavage of amyloid precursor protein.
Although a definitive diagnosis of AD requires micro-
scopic examination of brain tissue obtained at biopsy or 
autopsy, [4] recently approved amyloid-specific positron 
emission tomography (PET) radiotracers may facilitate 
in-life early detection or exclusion of amyloid plaques in 
a routine clinical setting. One of the first amyloid PET 
imaging agents was  [11C]Pittsburgh compound B  ([11C]
PiB), and it is probably the most widely studied agent. 
Its molecular structure is similar to thioflavin T, with 
modifications to allow it to cross the blood brain bar-
rier, resulting in excellent visualization of brain amyloid 
[5–9]. However, the short radioactive half-life of car-
bon-11 (~20  min) limits  [11C]PiB’s use to centers with 
on-site cyclotrons [10]. Efforts to develop radiotracers 
using the longer-lived positron-emitting isotope fluo-
rine-18 (radioactive t1/2 ~110 min) resulted in marketing 
authorization of three commercially available products: 
florbetapir, flutemetamol, and florbetaben. One of these, 
 [18F]flutemetamol (Vizamyl™, GE Healthcare, Marlbor-
ough, MA), recently gained regulatory approval in the 
USA and Europe as a diagnostic drug, and in Japan as a 
medical device for imaging neuritic amyloid plaques in 
the brain. The chemical structure of  [18F]flutemetamol is 
nearly identical to that of  [11C]PiB, differing only by the 
presence of the fluorine atom.
Prior clinical studies showed a strong correlation 
between cortical brain uptake of  [18F]flutemetamol and 
quantitative measures of amyloid burden, [11] an ability 
to detect brain amyloid comparable to that of  [11C]PiB, 
[12] and excellent sensitivity and specificity for detect-
ing/excluding amyloid [12–14]. The clinical development 
program that was the basis for US and European approv-
als enrolled 761 subjects. Of these, 27 (4%) were Asian, 
including 22 (14 healthy volunteers and 8  AD patients) 
that were enrolled in a Japanese Phase 1 study [15]. The 
Phase 2 study reported in this paper explored further the 
safety and efficacy of  [18F]flutemetamol in a larger Japa-
nese population which included healthy volunteers, patients 
with probable Alzheimer’s disease, and patients with mild 
cognitive impairment. A combined data set of 831 total 
subjects was the basis for approval in Japan. The design of 
the Phase 2 study in Japan was comparable to the design 
of the study performed for approval in the US and Europe 
and hence a comparison of these results of two studies was 
an important part of the Japanese approval process. Per-
formance of an amyloid PET agent across different geog-
raphies is important to document so that data and studies 
can be used for registration in multiple territories. The piv-
otal studies presented in all countries has been the autopsy 
verification study in end-of-life subjects where the sensitiv-
ity and specificity of  [18F]flutemetamol to detect β-amyloid 
in the brain were determined using neuropathologically 
determined neuritic plaque levels as the standard of truth 
[14]. In addition, two previous papers have described (a) 
the pharmacokinetics, biodistribution and internal radia-
tion dosimetry profiles and (b) exploratory brain uptake of 
 [18F]flutemetamol in Japanese subjects and have indicated 
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that the molecule behaves comparably in small pilot popu-
lations [15–18]. The study reported here was the phase-II 
clinical trial of  [18F]flutemetamol in Japan (GE-067-017) 
and it assessed the performance and safety of  [18F]flutemet-
amol when studied in a larger population of elderly con-




The primary objective of this study was to assess the per-
formance of Flutemetamol F 18 Injection in Japanese 
subjects as indicated by the level of agreement with clini-
cal diagnosis of the blinded visual interpretations of  [18F]
flutemetamol brain images made by the non-Japanese read-
ers. To determine if the performance of the tracer in Japa-
nese subjects was comparable to its performance in other 
geographic territories, the images were interpreted by non-
Japanese readers in the same way as in the previous studies 
in Europe and USA.
Secondary objectives included evaluation of agree-
ment between Japanese and non-Japanese readers in their 
blinded visual interpretations of  [18F]flutemetamol brain 
images; inter-reader agreement (IRA) and intra-reader 
reproducibility (IRR) of the blinded visual interpretation 
of  [18F]flutemetamol brain images; the distributions and 
mean values of quantitative image interpretations (stand-
ardized uptake value ratios [SUVRs]) of  [18F]flutemetamol 
brain images by the diagnostic subgroups (healthy volun-
teer [HV], amnestic mild cognitive impairment [aMCI], or 
pAD); test–retest variability in subjects with probable Alz-
heimer’s disease (pAD); association between SUVR and 
age in HVs; and safety of the drug product Flutemetamol 
F 18 Injection.
Subjects
A total of six enrolling sites participated in the study, 
of which three sites also imaged their subjects and the 
other three sites had their subjects imaged in one of the 
imaging sites not far from theirs. At each participating 
center, the study protocol and informed consent form 
was approved by the ethics committee prior to subject 
screening and enrollment and the study was performed 
according to the standards of Good Clinical Practice 
and principles of the Declaration of Helsinki. Written 
informed consent was obtained from each subject prior to 
any study-related procedures. The study aimed to enroll 
70 subjects of first-order Japanese descent with  [18F]
flutemetamol: 25 patients with pAD, 20 with aMCI, and 
25 cognitively normal HVs (10 younger HVs aged 55 or 
less and 15 older HVs over age 55).
Each subject had at least 6  years of education, ade-
quate visual, auditory and communication capabilities, 
and willingness and ability to comply with all study pro-
cedures, including standard tests of cognitive function. 
Each subject (and the caregiver, if relevant) was deemed 
by the investigator to be compliant and to have a high 
probability of completing the study. Women could not be 
of childbearing potential.
Subjects were excluded for unacceptable past radiation 
exposure; hypersensitivity to Flutemetamol F 18 Injec-
tion or any component; substance abuse; contraindica-
tion for MRI/PET; participation in a clinical trial of an 
investigational medicinal product within the past 30 days; 
positive serology for HBs, HCV, HIV, or syphilis; regu-
lar receipt of anticholinergic medication within the prior 
3 months; and history of head injury that might interfere 
with the PET image interpretation.
pAD subjects were ≥55 years of age and met National 
Institute of Neurological and Communicative Diseases 
and Stroke–Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ARDRA) criteria for pAD and the 
diagnostic and statistical manual of mental disorders-IV 
(DSM-IV) criteria for AD [19]. Other inclusion criteria 
for pAD subjects included: Mini Mental State Examina-
tion  (MMSE®) score range of 15–26, clinical dementia 
rating scale (CDR) score of 0.5–2, a score of ≤4 on the 
Modified Hachinski Ischemic scale, brain MRI consistent 
with AD, and an appropriate caregiver capable of accom-
panying the subject on all study visits.
aMCI subjects were ≥55 years of age and met the 
Petersen criteria for aMCI [20]. Additional inclusion cri-
teria were: MMSE of 27--30 and CDR of 0 or 0.5, a score 
of ≤4 on the Modified Hachinski Ischemic scale, brain 
MRI consistent with aMCI, and an appropriate caregiver 
capable of accompanying the subject on all study visits.
pAD and aMCI subjects were excluded for any of the 
following: a significant neurological or psychiatric disor-
der other than pAD that may affect cognition (including, 
but not limited to, major depression, schizophrenia, or 
mania); a previous history of clinically evident stroke, or 
significant cerebrovascular disease on brain imaging.
HVs were ≥25 years of age and had MMSE > 27, CDR 
0, no signs of cognitive impairment, and a normal brain 
MRI. Exclusion criteria were: any clinically significant 
medical or neurological condition or any clinically signif-
icant abnormality on physical, neurological or laboratory 
examination; or a family history of pAD (more than one 
first degree relative with the diagnosis of pAD).




The investigational medicinal product Flutemetamol F 18 
Injection was synthesized and handled according to Good 
Manufacturing Practice at two PET manufacturing sites, 
each located in the imaging site of this study, and was also 
transported to the third imaging site. Flutemetamol F 18 
Injection was administered intravenously as a bolus dose 
(<40  s) via the antecubital vein. For subjects receiving a 
single dose of Flutemetamol F 18 Injection, the admin-
istered activity was 185  MBq, based on previous Phase I 
results [15–17]. In one enrolling site, 5 pAD subjects were 
enrolled in the test–retest cohort and each received two 
120-MBq administrations of Flutemetamol F 18 Injection 
(for a cumulative total of 240 MBq).
MRI imaging
MRI was performed either on the screening day or at a sep-
arate visit but always prior to  [18F]flutemetamol PET imag-
ing to rule out cerebrovascular and structural disorders, as 
well as for volume-of-interest (VOI) analysis of the PET 
tracer uptake.
PET imaging
Three PET/CT scanners were used in the study: two GE 
Discovery 690 s and a Siemens Biograph 16. All scanners 
used iterative reconstruction and Gaussian post-reconstruc-
tion filtering to produce a net resolution of ~6 mm. Scan-
ning started approximately 90  min following administra-
tion of Flutemetamol F 18 Injection, and lasted for 30 min. 
Data were collected as 5-min frames and were summed 
for visual assessment and quantitative analysis. In subjects 
who underwent two scans, the two scans were separated by 
1–4 weeks and performed with the same scanner.
Image analysis
PET images were realigned to correct for inter-frame 
movement, summed to create a 30-min static image, and 
co-registered to the patient’s MRI. Each subject’s PET and 
MR images were spatially normalized to the ICBM152 
[21] template space for definition of VOIs for quantitative 
image analysis using SUVR, where the uptake of tracer 
in a VOI was divided by the uptake in the cerebellar cor-
tex (CER; primary reference region) or pons (alternative 
reference region). A composite SUVR was derived from 
the simple mean of the SUVRs of five anatomical regions 
outlined bilaterally (frontal cortex, anterior cingulate, pari-
etal cortex, lateral temporal cortex, and posterior cingulate 
and precuneus).
Blinded image evaluation
The blinded visual interpretation of PET images was con-
ducted by 10 independent physician readers (five non-Jap-
anese and five Japanese) who were experienced in nuclear 
medicine image interpretation. Japanese readers had been 
trained and board certified in Japan and were practicing 
currently in Japan, and non-Japanese readers had been 
trained and board certified outside of Japan and were prac-
ticing currently outside Japan. To be qualified as a reader, 
each candidate was trained to assess images using GE’s 
interactive electronic training program for the interpreta-
tion of  [18F]flutemetamol images including a classification 
test which had to be passed. The readers independently 
read and classified each study subject’s images as either 
normal or abnormal for neuritic plaque density in separate 
blinded image evaluation sessions for the non-Japanese and 
Japanese readers.
Safety assessments
Subjects were monitored for adverse events (AEs) from the 
start of the first administration of study tracer up to 24  h 
afterward. Vital signs (temperature, pulse, respiration, 
blood pressure), 12-lead electrocardiograms, and clini-
cal laboratory parameters were evaluated at pre-specified 
pre- and post-treatment time points. Each subject received 
a physical examination at screening and before and after 
scanning.
Statistical analyses
All statistical analyses were performed using  SAS® soft-
ware Version 9.2 (SAS Institute Inc., Cary, NC). For some 
analyses, HVs were stratified into two age groups; 10 
younger HVs (25–55 years) and 15 older HVs (≥55 years 
old).
Primary efficacy analysis
The primary efficacy analysis (based on the data from HVs 
and pAD subjects) was the agreement of the non-Japanese 
readers’ image interpretations with clinical diagnosis (used 
in lieu of having histopathology as the SoT), resulting in 
estimates of positive percent agreement (PPA; similar to 
sensitivity; determined in patients with a clinical diagno-
sis of AD) and negative percent agreement (NPA; similar 
to specificity; determined in the HV subjects). Each image 
interpretation for each subject was compared to his/her 
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clinical diagnosis and classified as an apparent True Posi-
tive (TP), True Negative (TN), False Positive (FP), or False 
Negative (FN) result, and the numbers of each classifica-
tion (nTP, nTN, nFP, nFN) were determined for each reader 
and used to calculate PPA and NPA for each reader using 
the following formulas:
Positive Percent Agreement (PPA) = nTP/(nTP + nFN).
Negative Percent Agreement (NPA) = nTN/(nFP + nTN).
Majority of image interpretations were determined from 
image interpretation made independently by the major-
ity (i.e., at least 3) of 5 readers in the reader group (non-
Japanese or Japanese) being analyzed. For example, if 3, 
4, or 5 of the readers independently interpreted a subject’s 
PET image as “normal”, then the majority interpretation of 
that image was “normal”. Majority of image interpretations 
were classified as TP, TN, FP, or FN and majority values 
for PPA and NPA were determined as described above.
Inter‑reader agreement (IRA)
Pair-wise IRA of blinded visual image interpretation was 
determined as Cohen’s kappa, [22] and classified as excel-
lent (>0.9), very good (>0.8 and ≤0.9), or good (>0.7 and 
≤0.8). Agreement across all non-Japanese readers and Jap-
anese readers was determined as Fleiss’ kappa.
Intra‑reader reproducibility (IRR)
IRR was measured as the percentage of images for which a 
reader’s second interpretation of an image agreed with the 
reader’s first interpretation of the image. This was deter-
mined using duplicate images for seven subjects (approxi-
mately10%) drawn randomly from the 65 subjects who 
received single administrations of Flutemetamol F 18 
Injection. The duplicate images were inserted randomly 
into the image set interpretated by each reader.
Quantitative assessment—SUVR
SUVR measurements of  [18F]flutemetamol brain images 
were used to quantify brain uptake of the tracer. SUVR 
was defined as the ratio of each target region’s standardized 
uptake value (SUV) to the SUV in a reference region; this 
was calculated using internally developed software. SUVs 
for the target and reference regions were obtained from the 
VOI values by normalizing average tissue concentration in 
the VOI by the injected administration and weight of the 
subject using the following formula:
SUV = Measured Activity Concentration in VOI / 
Injected activity / Weight of subject.
SUVR was determined separately for the cerebellar cor-
tex (SUVR-CER) and the pons (SUVR-PONS) as reference 
regions. Composite SUVR values representing all regions 
analyzed were calculated by simple averaging of the SUVR 
values for the anterior cingulate, frontal cortex, parietal 
cortex, lateral temporal cortex and precuneus/posterior cin-
gulate regions.
Calculation of optimal thresholds
The mean and standard deviation (SD) for SUVR were cal-
culated region-wise for the pAD group and HV group sepa-
rately. The data were checked for outliers and none were 
identified.
In each region, the optimal SUVR threshold (OSUVRT) 
was defined as the SUVR that resulted in the maximum 
percentage of correctly classified HV and pAD subjects. 
The OSUVRTs were calculated by locating the exact mid-
point expressed in SDs between the mean SUVRs of the 
pAD and HV groups:
OSUVRT = [meanpAD − (factor × SDpAD)].
where:
factor = [meanpAD − meanHV] / [SDpAD + SDHV].
Determination of PPA and NPA Using SUVR values
Composite SUVR-CER values for pAD and HV subjects 
were classified as abnormal (positive) if they were above 
the optimal SUVR threshold and normal (negative) if they 
were at or below the optimal SUVR threshold. The SUVR-
CER classifications were compared to clinical diagnosis 
and sub-classified as TN, TP, FP, or FN, and the numbers 
of each sub-classification were used to calculate PPA and 
NPA, which are reported with exact binomial 95% confi-
dence intervals.
Test–retest variability
Test–retest variability (TRV) was determined for five pAD 
subjects who each received two 120-MBq administrations 
of Flutemetamol F 18 Injection and subsequent PET scans 
(1–4 weeks apart). Percent TRV was calculated as the abso-
lute value of the difference between the first (test) value and 
the second (retest) value divided by the mean and multi-
plied by 100 percent:
%TRV = 100% × |  SUVR1 −SUVR2|/((SUVR1 + SUVR2)/2).
In the case of perfect agreement,  SUVR1 and  SUVR2 
would be equal, and %TRV would be 0%, indicating no 
variability. The variability estimate was calculated for each 
subject, for each brain VOI and the composite measure.
Association between SUVR and Age
The association between the composite SUVR and the age 
of HV subjects was determined by Pearson’s correlation (r) 
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and a regression model of the SUVR as the dependent vari-
able and subject age as the independent variable.
Classification of aMCI Subjects’ Images
The classification of aMCI subjects’ images as normal or 
abnormal is presented descriptively with number and per-
centage. This assessment was provided based on both vis-
ual interpretation and composite SUVR compared to the 
optimal regional thresholds.
Results
In total, 87 Japanese subjects (28 pAD, 23 aMCI and 36 
HVs) at six centers (five in Japan, one in Korea) signed 
informed consent and were enrolled in this study; 17 
withdrew before dosing, 13 due to screen failure. Seventy 
subjects received Flutemetamol F 18 Injection, and all 70 
completed the study and were included in both the efficacy 
and safety populations. Demographic and baseline neu-
ropsychological data are summarized in Table 1.
Among the non-Japanese readers, PPA was 92% (95% 
CI, 74, 99) for all readers and NPA ranged from 96% (95% 
CI, 80%, 100%) to 100% (95% CI, 86%, 100%) (median, 
100%; majority 100% [95% CI, 86%, 100%]). The area 
under the reader performance curve (analogous to a 
receiver operating characteristic [ROC] curve) was 0.96, 
close to that of a perfect test, which would have an area of 
1.
Among the Japanese readers, PPA ranged from 88% 
(95% CI, 69, 98%) to 92% (95% CI, 74, 99%) (median, 
92%; majority 92% [95% CI, 74, 99%]) and NPA ranged 
from 96% (95% CI, 80, 100%) to 100% (95% CI, 86, 100%) 
(median, 96%; majority 96% [95% CI, 80, 100%]). The area 
under the reader performance curve is 0.96. PPA and NPA 
for Japanese and non-Japanese readers were comparable 
(Fig. 1).
Table 1  Summary of Subject Demographics and Baseline Neuropsychological Status – Safety Population
AD Alzheimer’s disease, BMI body mass index, CDR Clinical Dementia Rating, DSM‑IV Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition, HV healthy volunteer, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, N safety population, n number of 
subjects in category, NA not applicable, NC unable to be calculated, NINCDS‑ADRDA National Institute of Neurological and Communicative 
Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association, SD standard deviation, %, 100% × n/N
a Age was calculated as [Date of Informed Consent—Date of Birth] / 365.25 rounded down to the nearest integer
Variable Statistics/cat-
egory






≤55 years N = 10 >55 years N = 15 All HV N = 25
Age (years)a n 25 20 10 15 25 70
Mean (SD) 75 (6) 71 (7) 50 (8) 63 (6) 57 (9) 68 (11)
≤55 years, n (%) 0 (0) 0 (0) 10 (100) 0 (0) 10 (40) 10 (14)
>55 years, n (%) 25 (100) 20 (100) 0 (0) 15 (100) 15 (60) 60 (86)
Gender, n (%) Male 9 (36) 11 (55) 6 (60) 8 (53) 14 (56) 34 (49)
Female 16 (64) 9 (45) 4 (40) 7 (47) 11 (44) 36 (51)
Race, n (%) Japanese 25 (100) 20 (100) 10 (100) 15 (100) 25 (100) 70 (100)
Height (cm) n 25 20 10 15 25 70
Mean (SD) 156 (7) 158 (10) 165 (7) 163 (10) 163 (9) 159 (9)
Weight (kg) n 25 20 10 15 25 70
Mean (SD) 53 (10) 56 (9) 66 (11) 59 (9) 62 (11) 57 (11)
BMI (kg/m2) n 25 20 10 15 25 70
Mean (SD) 22 (3) 23 (3) 25 (4) 22 (3) 23 (3) 23 (3)
MMSE n 25 20 10 15 25 70
Mean (SD) 21.1 (3.07) 28.4 (0.81) 30.0 (0.00) 29.9 (0.35) 29.9 (0.28) 26.3 (4.40)




n 25 20 NA NA NA 45
Mean (SD) 0.7 (0.69) 0.8 (0.70) – – – 0.7 (0.69)
95% CI 0.4, 1.0 0.5, 1.1 – – – 0.5, 0.9
CDR n 25 20 10 15 25 70
Mean (SD) 0.94 (0.391) 0.38 (0.222) 0.00 (0.000) 0.00 (0.000) 0.00 (0.000) 0.44 (0.478)
95% CI 0.78, 1.10 0.27, 0.48 NC NC NC 0.33, 0.56
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IRA values (Table 2, S1) showed high levels of agree-
ment across readers. Among the non-Japanese readers, 
percentage agreement for reader pairs ranged from 95 to 
100%, with a median of 99%. Cohen’s kappa scores (95% 
CI) ranged from 0.91 (0.80, 1.00) to 1.00 (1.00, 1.00), 
with a median of 0.97 (0.91, 1.00). Across all five non-
Japanese readers, there was complete agreement for 95% 
of images read; Fleiss’ kappa (95% CI) was 0.96 (0.89, 
1.00).
Among the Japanese readers, percentage agreement for 
reader pairs ranged from 95 to 99%, with a median of 97%. 
Cohen’s kappa scores (95% CI) ranged from 0.91 (0.80, 
1.00) to 0.97 (0.91, 1.00), with a median of 0.94 (0.85, 
1.00). Across all five Japanese readers, there was complete 
agreement for 94% of images read; Fleiss’ kappa (95% CI) 
was 0.94 (0.86, 1.00). IRR (Table  3) was 7/7 (100%) for 
Fig. 1  Blinded Visual Interpretations for Non-Japanese and Japa-
nese Readers—efficacy population. a positive percent agreement. b 
Negative percent agreement. The analyses are based on blinded visual 
interpretations of the images collected after the first dose of Flutemet-
amol F 18 Injection. Error bars represent 95% exact binomial con-
fidence interval. *Majority interpretation by non-Japanese readers 
(Readers A, B, C, D and E). ^Majority interpretation by Japanese 
readers (Readers F, G, H, I and J)
Table 2  Summary of Inter-reader agreement (ira)—efficacy popula-
tion
Comparison Statistic Percent Kappa (95% CI)
Non-Japanese to Non-Japanese Min 95 0.91 (0.80, 1.00)
Max 100 1.00 (1.00, 1.00)
Median 99 0.97 (0.91, 1.00)
Japanese to Japanese Min 95 0.91 (0.80, 1.00)
Max 99 0.97 (0.91, 1.00)
Median 97 0.94 (0.85, 1.00)
Non-Japanese to Japanese Min 94 0.88 (0.76, 0.99)
Max 100 1.00 (1.00, 1.00)
Median 97 0.94 (0.85, 1.00)
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four of the five readers in each group, and was 6/7 (86%) 
for the remaining reader in each group.
Quantitative analysis by SUVR (Table 4) showed some 
clear trends. The ordering of mean regional and compos-
ite SUVR values, from highest to lowest values, was: 
pAD > MCI > EHV > YHV, consistent with the known 
association of amyloid burden and diagnosis. Because of 
the large difference in SUVR values, there was clear dif-
ferentiation between subjects with pAD and HVs, in all 
cortical regions and in the composite VOI. There was less 
differentiation between subjects with pAD and those with 
aMCI, related to the smaller differences in SUVR. Despite 
the smaller differences, none of the 95% CIs for the pAD 
and the aMCI subjects overlapped, indicating a statistically 
meaningful difference (although no formal hypothesis test 
was performed) between the mean SUVRs. Within each 
cohort, the order of SUVR values, from highest to lowest, 
was: posterior cingulate > anterior cingulate > lateral tem-
poral > parietal ≈ frontal. Results using mean SUVR-PONS 
values were similar to those using SUVR-CER (data not 
shown).
The OSUVRTs for cerebellum and pons (OSUVRT-
CER and OSUVRT-PONS, respectively) for the composite 
VOI were 1.357 and 0.596, respectively. Using OSUVRT-
CER, PPA and NPA were 96% (95% CI, 80, 100%) and 
88% (95% CI 69, 98%), respectively. Using OSUVRT-
PONS, PPA and NPA were 92% (95% CI 74, 99%) and 
92% (95% CI 74, 99%), respectively. There was 85–100% 
of agreement between the visual image classifications by 
majority read assessment and the classification based on 
the optimal SUVR threshold.
For the 5 subjects with pAD who received a second 
dose of Flutemetamol F 18 Injection, SUVR-CER values 
following the second dose were similar to those seen fol-
lowing the first dose (data not shown), resulting in %TRV 
values that ranged from 1.85 to 2.27% for SUVR-CER and 
1.14–2.11% for SUVR-PONS. Test–retest agreement of the 
blinded visual interpretations was 100% for each of the ten 
readers.
The trend for higher SUVR values in older subjects evi-
dent in Table 4 was confirmed and quantified through cor-
relation analysis. There was significant correlation between 
SUVR-CER and age, with a Pearson correlation coefficient 
of 0.5527 (p = 0.0042, Fig.  2). A regression model con-
firmed the correlation between SUVR-CER and age, 
with R2 = 0.3055. The correlation between SUVR-PONS 
and age approached but did not achieve statistical signifi-
cance (Pearson correlation coefficient 0.3731 [p = 0.0662], 
R2 = 0.1392).
Table  5 summarizes the image interpretations for the 
20 aMCI subjects. Approximately half (45–55%) were 
assigned to each category. Based on the optimal SUVR 
threshold classification, 13 (65%) subjects’ scans were 
abnormal and 7 (35%) were normal using the optimal 
SUVR-CER threshold classification, and 10 (50%) sub-
jects’ scans were abnormal and 10 (50%) were normal 
using the optimal SUVR-PONS threshold classification.
Example images are provided in Fig.  3 (negative) and 
Fig. 4 (positive).
Safety
Single and repeat doses of Flutemetamol F 18 Injection 
were generally well-tolerated by HVs and subjects with 
pAD and aMCI. AEs were reported in seven subjects (10%; 
Table 6). Two subjects (both HVs >55 years) experienced 
AEs that were deemed related to Flutemetamol Injection by 
the investigator: one subject experienced epigastric discom-
fort, flushing and hypertension, and another subject experi-
enced headache.
All AEs were mild and all events resolved. There were 
no deaths, serious AEs, or withdrawals due to AEs. No 
clinically significant changes were reported in laboratory 
parameters, ECG, neurological or physical examinations. 
One subject had a clinically significant change in blood 
pressure that was mild in intensity and resolved, and was 
judged to be unrelated to the administration of Flutemeta-
mol F 18 Injection.
Discussion
This Phase 2, multicenter study in three groups of Japa-
nese subjects (HVs, aMCI, and pAD) showed high levels 
of agreement between the subject’s clinical diagnosis and 
the blinded visual interpretation of  [18F]flutemetamol brain 
images, as indicated by the high values for PPA (analogous 
to sensitivity) and NPA (analogous to specificity). The 
area under the reader performance curve was 0.96 for both 
groups of readers, indicating identical and nearly perfect 
overall performance; this is also evident from the nearly 
complete overlap in the 95% confidence intervals across the 
two groups of readers (Fig.  1). Two (8%) of the 25 pAD 
subjects diagnosed by clinical criteria were  [18F]flutemet-
amol negative, whereas none of the HVs were deemed to 
have  abnormal[18F]flutemetamol uptake above threshold 
Table 3  Summary of intra-
reader reproducibility (IRR)—
efficacy population
Reader IRR, n (%)
Non-Japanese
 A, C, D, E 7 (100)
 B 6 (86)
Japanese
 G, H, I, J 7 (100)
 F 6 (86)
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Table 4  Summary of SUVR by region and clinical diagnosis for cerebellum reference region—efficacy population
AD Alzheimer’s disease, CI confidence interval, HV healthy volunteer, MCI mild cognitive impairment, N efficacy population, n number of sub-
jects in category, NA not applicable, SD standard deviation, SUVR standardized uptake value ratio, VOI volume of interest
a Composite VOI determined from the anterior cingulate, frontal cortex, parietal cortex, lateral temporal cortex and a VOI covering precuneus 
and posterior cingulate
First dose of Flutemetamol F 18 injection (185 MBq)






≤55 years >55 years All HV
N = 10 N = 15 N = 25
Anterior cingulate 
cortex
n 20 20 10 15 25 65
Mean (SD) 2.19 (0.518) 1.71 (0.332) 1.15 (0.084) 1.29 (0.134) 1.23 (0.133) 1.68 (0.528)
95% CI 1.95, 2.43 1.56, 1.87 1.09, 1.21 1.21, 1.36 1.18, 1.29 1.54, 1.81
Frontal cortex n 20 20 10 15 25 65
Mean (SD) 1.95 (0.429) 1.52 (0.301) 1.08 (0.066) 1.13 (0.089) 1.11 (0.083) 1.49 (0.454)
95% CI 1.75, 2.15 1.38, 1.66 1.04, 1.13 1.084, 1.182 1.08, 1.15 1.38, 1.61
Lateral temporal 
cortex
n 20 20 10 15 25 65
Mean (SD) 1.98 (0.370) 1.56 (0.250) 1.17 (0.068) 1.27 (0.073) 1.23 (0.085) 1.56 (0.401)
95% CI 1.81, 2.15 1.44, 1.68 1.12, 1.22 1.23, 1.31 1.19, 1.26 1.46, 1.66
Parietal cortex n 20 20 10 15 25 65
Mean (SD) 1.88 (0.366) 1.51 (0.282) 1.09 (0.039) 1.18 (0.094) 1.15 (0.088) 1.48 (0.399)
95% CI 1.71, 2.05 1.38, 1.64 1.07, 1.12 1.13, 1.24 1.11, 1.18 1.39, 1.58
Posterior cingular 
cortex
n 20 20 10 15 25 65
Mean (SD) 2.27 (0.487) 1.76 (0.370) 1.18 (0.079) 1.32 (0.122) 1.26 (0.126) 1.72 (0.541)
95% CI 2.04, 2.50 1.58, 1.93 1.12, 1.24 1.25, 1.39 1.21, 1.32 1.59, 1.86
Composite VOI a n 20 20 10 15 25 65
Mean (SD) 2.05 (0.424) 1.61 (0.297) 1.13 (0.056) 1.24 (0.082) 1.20 (0.088) 1.59 (0.459)
95% CI 1.86, 2.25 1.47, 1.75 1.09, 1.18 1.19, 1.28 1.16, 1.23 1.48, 1.70
First dose of Flutemetamol F 18 injection (all subjects)






≤55 years >55 years All HV
N = 10 N = 15 N = 25
Anterior cingulate 
cortex
n 25 20 10 15 25 70
Mean (SD) 2.20 (0.466) 1.71 (0.332) 1.15 (0.084) 1.29 (0.134) 1.23 (0.133) 1.72 (0.530)
95% CI 2.01, 2.39 1.56, 1.87 1.09, 1.21 1.21, 1.36 1.18, 1.29 1.59, 1.84
Frontal cortex n 25 20 10 15 25 70
Mean (SD) 1.96 (0.393) 1.52 (0.301) 1.08 (0.066) 1.13 (0.089) 1.11 (0.083) 1.53 (0.459)
95% CI 1.80, 2.12 1.38, 1.66 1.04, 1.13 1.08, 1.18 1.08, 1.15 1.42, 1.64
Lateral temporal 
cortex
n 25 20 10 15 25 70
Mean (SD) 2.00 (0.348) 1.56 (0.250) 1.17 (0.068) 1.267 (0.073) 1.23 (0.085) 1.60 (0.412)
95% CI 1.85, 2.14 1.44, 1.68 1.12, 1.22 1.23, 1.31 1.19, 1.26 1.50, 1.70
Parietal cortex n 25 20 10 15 25 70
Mean (SD) 1.90 (0.348) 1.51 (0.282) 1.09 (0.039) 1.18 (0.094) 1.15 (0.088) 1.52 (0.412)
95% CI 1.76, 2.05 1.38, 1.64 1.07, 1.12 1.13, 1.24 1.11, 1.18 1.42, 1.62
Posterior cingular 
cortex
n 25 20 10 15 25 70
Mean (SD) 2.28 (0.451) 1.76 (0.370) 1.18 (0.079) 1.32 (0.122) 1.26 (0.126) 1.77 (0.548)
95% CI 2.09, 2.46 1.58, 1.93 1.12, 1.24 1.25, 1.39 1.21, 1.32 1.64, 1.90
Composite VOI 1 n 25 20 10 15 25 70
Mean (SD) 2.07 (0.390) 1.61 (0.297) 1.13 (0.057) 1.24 (0.082) 1.20 (0.088) 1.63 (0.466)
95% CI 1.91, 2.23 1.47, 1.75 1.09, 1.18 1.19, 1.28 1.16, 1.23 1.52, 1.74
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values either by visual inspection or by quantitative means. 
Fleiss’ kappa scores near one indicated excellent IRA, and 
eight of ten readers had IRRs of 100%.
The efficacy of Flutemetamol F 18 Injection in this 
study is consistent with the results of a previously reported 
Phase 2 study in Western subjects [12]. In that study, only 
two out of 27 of the probable AD subjects had a negative 
scan indicating that expert clinical diagnosis was a useful 
surrogate for neuropathology as a standard of truth to cal-
culate positive percent agreement. The term positive per-
cent agreement was used in this Japanese study instead of 
sensitivity as this Japanese study used clinical diagnosis as 
the standard of truth as opposed to neuropathology which 
was used for sensitivity measurements in the pivotal phase 
III study described by Curtis et al. [14] These results were 
expected given the lack of ethnic differences in the density 
and distribution of hallmark lesions of AD, [23] and agree-
ment on clinical diagnoses of dementia and dementia sub-
types in Japanese and western populations when the Amer-
ican Psychiatric Association’s Diagnostics and Statistics 
Manual criteria were used [24]. The demonstration that the 
 [18F]flutemetamol drug product performs comparably in 
both the Phase I and Phase II studies allowed the develop-
ment program to use the Curtis study [14] autopsy patients 
as the pivotal data set for the registration of Flutemetamol 
F 18 Injection in Japan.
The main strength of this study is its comparisons of 
image interpretations made by Japanese readers relatively 
Fig. 2  Composite SUVR Values and Age for HV subjects (efficacy 
population) [Clinical diagnosis at screening as HV (N = 25)] Using 
a cerebellum reference region (SUVR-CER), and b Pons Refer-
ence Region (SUVR-PONS). For the cerebellum reference region, 
the regression line was plotted based on SUVR = 0.8931 + 0.0053 
*AGE with R2 = 0.3055. For the pons reference region, the regres-
sion line was plotted based on SUVR = 0.4013 + 0.0019 *AGE with 
R2 = 0.1392. HV, healthy volunteer; SUVR, standardized uptake value 
ratio.
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Table 5  Summary of 
determination of aMCI 
subjects—efficacy population
aMCI amnestic mild cognitive impairment, HV healthy volunteer, N efficacy population, n number of sub-
jects in category, pAD probable Alzheimer’s disease, SUVR standardized uptake value ratio, SUVR‑CER, 
SUVR based on the cerebellum as reference region, SUVR‑PONS, SUVR based on the pons as reference 
region
a The optimal SUVR threshold was calculated as:  SUVROT,  [meanpAD − factor x  SDpAD], where factor, 
 [meanpAD –  meanHV] /  [SDpAD +  SDHV]. If SUVR-CER > 1.357 or SUVR-PONS > 0.596, the SUVR was 
defined as “abnormal.”
Assessment N = 20
Abnormal (positive) n (%) Normal 
(negative) 
n (%)
Blinded visual read (non-Japanese readers)
 Reader A 9 (45) 11 (55)
 Reader B 10 (50) 10 (50)
 Reader C 9 (45) 11 (55)
 Reader D 9 (45) 11 (55)
 Reader E 10 (50) 10 (50)
Blinded visual read (Japanese readers)
 Reader F 11 (55) 9 (45)
 Reader G 10 (50) 10 (50)
 Reader H 11 (55) 9 (45)
 Reader I 11 (55) 9 (45)
 Reader J 11 (55) 9 (45)
 Optimal SUVR-CER threshold  classificationa 13 (65) 7 (35)
 Optimal SUVR-PONS threshold  classificationa 10 (50) 10 (50)
Fig. 3  Example negative images
Fig. 4  Example positive images
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new to flutemetamol to those of more experienced read-
ers, which showed that after a short training session, the 
Japanese image readers were as good as the non-Japanese 
readers.
The main weaknesses of this study include lack of a true 
standard of truth based on brain examination (which was 
considered unnecessary for the study goals), and use of 
younger HVs, which may have made it easier to differenti-
ate between AD and HV subjects. However, because there 
was no histological standard of truth, the use of younger 
HVs may have helped avoid including cognitively normal 
HVs with asymptomatic brain amyloid, which may have 
confounded the results.
Test–retest reproducibility is an important determinant 
of the utility of an assay for longitudinal within-subject 
studies. The variability in test–retest SUVR was very low 
(less than 2.3%), and agreement in visual interpretations 
among readers was excellent. Overall, the test–retest vari-
ability of  [18F]flutemetamol scans in pAD patients was sim-
ilar between the Japanese and Western subjects as reported 
by Vandenberghe et al. [12].
As expected from results with other tracers such as  [11C]
PiB, mean SUVR was consistently lower in HVs compared 
to the patients with aMCI or pAD. Moreover, the range of 
SUVR values in Japanese HVs and cases with pAD over-
lapped with the range reported previously in the Western 
HVs and cases with pAD, respectively [12]. Subjects with 
aMCI demonstrated an SUVR distribution similar to that 
observed in Western subjects with MCI (i.e., a roughly 
50:50 split between normal and abnormal scans). Strong 
agreement between quantitation (SUVR) and visual image 
classification was observed. Based on the absence of sig-
nificant AEs related to Flutemetamol F 18 Injection, the 
results suggest that Flutemetamol F 18 Injection is safe and 
generally well tolerated by Japanese HVs and subjects with 
pAD and aMCI.
In conclusion,  [18F]flutemetamol uptake allowed differ-
entiation between Japanese patients with pAD and younger 
healthy controls. The results are similar to those reported in 
the Western population, giving no evidence of specific eth-
nic differences in the efficacy or safety of Flutemetamol F 
18 Injection. After a short training period, Japanese readers 
were as proficient as more experienced non-Japanese read-
ers. Overall, the results from this study show that Flutemet-
amol F 18 Injection is a robust tracer for in vivo detection 
of an increased brain β-amyloid load.
Acknowledgements The study was entirely sponsored by GE 
Healthcare (GEHC). Author Heurling was a full-time employee of 
GE Healthcare when the data were analyzed and the manuscript pre-
pared. Authors Zanette and Sherwin are full-time employees of GE 
Healthcare. All other authors were compensated for being investiga-
tors in the study but declare no other conflicts of interest. Authors 
Table 6  Overall summary of adverse events
AEs adverse events, aMCI amnestic mild cognitive impairment, HV healthy volunteers, N safety population, n number of subjects in category, 
pAD probable Alzheimer’s disease, AE adverse event, %, 100% × n/N. Subjects reporting more than one event in a category are counted only 
once for that category
a Subjects reporting more than one event are counted only once at the highest intensity reported
Clinical diagnosis at screening
Healthy volunteer
pAD 
N = 25 n 
(%)
aMCI 
N = 20 n 
(%)
≤55 
yearsN = 10 
n (%)
>55 years 
N = 15 n 
(%)
All HV 
N = 25 n 
(%)
Total N = 70 n (%)
Number of AEs reported 2 2 0 5 5 9
Subjects with any AE 2 (8) 2 (10) 0 (0) 3 (20) 3 (12) 7 (10)
Subjects with any AE at least possibly related to Flutemetamol 
F 18 injection
0 (0) 0 (0) 0 (0) 2 (13) 2 (8) 2 (3)
Subjects with AEs by  intensitya
 Mild 2 (8) 2 (10) 0 (0) 3 (20) 3 (12) 7 (10)
 Moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Severe 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Subjects with Any Serious AE 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Subjects with any serious AE at least possibly related to 
Flutemetamol F 18 injection
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Subjects with any AE leading to study discontinuation 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Subjects with any AE leading to death 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Subjects with any ae leading to death at least possibly related 
to Flutemetamol F 18 injection
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
272 Ann Nucl Med (2017) 31:260–272
1 3
Miki, Shimada, Senda, Kim, Yamamoto, Sugino, and Kowa made 
substantial contributions to the acquisition of data for the work, revis-
ing the manuscript critically for important intellectual content, giving 
final approval of the version to be published, and agree to be account-
able for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately 
investigated and resolved. Authors Zanette, Heurling, and Sherwin 
were involved in the conception and design of the study, analysis and/
or interpretation of the data, drafting and revising the manuscript for 
important intellectual content, giving final approval of the version 
to be published, and agree to be accountable for all aspects of the 
work in ensuring that questions related to the accuracy or integrity 
of any part of the work are appropriately investigated and resolved. 
GE employees Christopher J. Buckley PhD and Gillian Farrar PhD 
reviewed the manuscript and provided helpful comments.
Funding The study was sponsored entirely by GE Healthcare 
(GEHC).
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Matsui Y, Tanizaki Y, Arima H, Yonemoto K, Doi Y, Ninomiya 
T, et al. Incidence and survival of dementia in a general popula-
tion of Japanese elderly: the Hisayama study. J Neurol Neurosurg 
Psychiatry. 2009;80(4):366–70.
 2. Yamada M, Mimori Y, Kasagi F, Miyachi T, Ohshita T, Sudoh 
S, et  al. Incidence of dementia, Alzheimer disease, and vas-
cular dementia in a Japanese population: Radiation Effects 
Research Foundation adult health study. Neuroepidemiology. 
2008;30(3):152–60.
 3. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland 
JR, Dartigues JF, et al. Incidence of dementia and major subtypes 
in Europe: a collaborative study of population-based cohorts. 
Neurologic Diseases in the Elderly Research Group. Neurology. 
2000;54(11 Suppl 5):S10–5.
 4. National Institute on Aging. About Alzheimer’s disease: diag-
nosis. http://www.nia.nih.gov/alzheimers/topics/diagnosis. 
Accessed 5 Sept 2014.
 5. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price 
JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-
PET amyloid imaging in a typical case of Alzheimer’s disease. 
Brain. 2008;131(Pt 6):1630–45.
 6. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt 
DP, et  al. Imaging brain amyloid in Alzheimer’s disease with 
Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19.
 7. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao 
L, et al. The binding of 2-(4′-methylaminophenyl)benzothiazole 
to postmortem brain homogenates is dominated by the amyloid 
component. J Neurosci. 2003;23(6):2086–92.
 8. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, 
Nagren K, et al. Assessment of beta-amyloid in a frontal corti-
cal brain biopsy specimen and by positron emission tomography 
with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 
2008;65(10):1304–9.
 9. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, 
et  al. PIB is a non-specific imaging marker of amyloid-beta 
(Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130(Pt 
10):2607–15.
 10. Laforce R Jr, Rabinovici GD. Amyloid imaging in the differen-
tial diagnosis of dementia: review and potential clinical applica-
tions. Alzheimers Res Ther. 2011;3(6):31.
 11. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Tro-
janowski JQ, et  al. Association between in  vivo fluorine 
18-labeled flutemetamol amyloid positron emission tomography 
imaging and in vivo cerebral cortical histopathology. Arch Neu-
rol. 2011;68(11):1398–403.
 12. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, 
Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer 
disease and mild cognitive impairment: a phase 2 trial. Ann Neu-
rol. 2010;68(3):319–29.
 13. Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hay-
akawa H. [18F]Flutemetamol amyloid-beta PET imaging com-
pared with [11C]PIB across the spectrum of Alzheimer’s dis-
ease. Eur J Nucl Med Mol Imaging. 2014;41(2):290–300.
 14. Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh 
MN, et al. Phase 3 trial of flutemetamol labeled with radioactive 
fluorine 18 imaging and neuritic plaque density. JAMA. Neurol. 
2015;72(3):287–94.
 15. Senda M, Yamamoto Y, Sasaki M, Yamane T, Brooks DJ, Farrar 
G, et  al. An exploratory efficacy study of the amyloid imaging 
agent [(18)F]flutemetamol in Japanese Subjects. Ann Nucl Med. 
2015;29(5):391–9.
 16. Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke 
M, Brooks DJ, et  al. Whole-body biodistribution and radiation 
dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid 
imaging. J Nucl Med. 2009;50(5):818–22.
 17. Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbul-
cke M, Koole M, et  al. Phase 1 study of the Pittsburgh com-
pound B derivative 18F-flutemetamol in healthy volunteers 
and patients with probable Alzheimer disease. J Nucl Med. 
2009;50(8):1251–9.
 18. Senda M, Brooks DJ, Farrar G, Somer EJ, Paterson CL, Sasaki 
M, et al. The clinical safety, biodistribution and internal radiation 
dosimetry of flutemetamol ((1)(8)F) injection in healthy Japa-
nese adult volunteers. Ann Nucl Med. 2015;29(7):627–35.
 19. American Psychiatric Association. Diagnostic and statistical 
manual of mental disorders: DSM- IV. 4th ed. Washington, DC: 
American Psychiatric Association; 1994.
 20. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, 
Kokmen E. Mild cognitive impairment: clinical characterization 
and outcome. Arch Neurol. 1999;56(3):303–8.
 21. Fonov VS, Evans AC, McKinstry RC, Almli CR, Collins DL. 
Unbiased nonlinear average age-appropriate brain templates 
from birth to adulthood. Neuroimage. 2009;47(Suppl 1):S102.
 22. Cohen J. A coefficient of agreement for nominal scales. Educ 
Psychol Meas. 1960;20:37–46.
 23. Sandberg G, Stewart W, Smialek J, Troncoso JC. The preva-
lence of the neuropathological lesions of Alzheimer’s dis-
ease is independent of race and gender. Neurobiol Aging. 
2001;22(2):169–75.
 24. Larson EB, McCurry SM, Graves AB, Bowen JD, Rice MM, 
McCormick WC, et al. Standardization of the clinical diagnosis 
of the dementia syndrome and its subtypes in a cross-national 
study: the Ni-Hon-Sea experience. J Gerontol A Biol Sci Med 
Sci. 1998;53(4):M313-9.
